What Lomoh Treats: Main Uses and Benefits

Lomoh is prescribed to provide essential supportive and therapeutic management in clinical situations where there is a high risk or presence of dangerous blood clotting. Its use is relevant across therapeutic areas, including the management of Venous Thromboembolism (VTE) and Acute Coronary Syndromes (ACS).

The medication is commonly used for managing conditions characterized by established, acute blood clots like Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and is also applied proactively for patients with severely restricted mobility after major surgery or acute medical illness. It may help reduce the risk of further ischemic complications in heart tissue for patients with Unstable Angina or certain Myocardial Infarction types.

“The role of this supportive therapy may assist with maintaining a sense of stability when symptoms are more noticeable and helps mitigate risks associated with clot progression.”

Quick Fact: Support for Thrombotic Risk

The use of Lomoh may assist with the management of risks related to abnormal blood clot formation, contributing to functional stability during symptomatic periods and contributes to easing the overall symptom load during acute vascular episodes.

Regulatory References

1. DailyMed (NIH) Label Information for Enoxaparin Sodium

Lomoh (Enoxaparin Sodium) is an anticoagulant. Its eligibility for use is strictly defined by government regulatory authorities based on pre-existing bleeding risk and specific medical conditions.

Contraindicated Populations

Use of Lomoh is prohibited in patients with:

• Active Major Bleeding.
• A confirmed history of immune-mediated Heparin-Induced Thrombocytopenia (HIT) within the last 100 days or in the presence of circulating antibodies.
• Known hypersensitivity to enoxaparin sodium, heparin, or pork products.
• Patients undergoing or anticipating neuraxial anesthesia (e.g., spinal or epidural) or spinal puncture, due to the serious risk of spinal hematoma.

Restricted or Conditional Use

Use is allowed but requires caution or dosage adjustment in the following groups:

• Severe Renal Impairment: Patients with creatinine clearance less than 30 mL/min require a dose adjustment due to the risk of drug accumulation.
• Older Adults (Geriatric): Use is permitted, but careful monitoring is advised due to an increased risk of bleeding.
• Pregnancy: The multi-dose vial containing benzyl alcohol is contraindicated in pregnant women. Pregnant women with mechanical prosthetic heart valves require close monitoring.
• Pediatric Patients: Safety and effectiveness have not been established in this population, and use is generally not recommended.

Interactions with other medicines and products

This section outlines the documented interaction profile for Lomoh (Enoxaparin Sodium) based on authoritative government regulatory labeling.

Exposure and Bleeding Risk Modifiers The primary interaction concern involves drugs that increase the risk of hemorrhage due to additive effects on blood clotting or platelet function. Co-administration with anticoagulants such as warfarin sodium and thrombolytic agents significantly increases this risk. Similarly, co-administration with products that affect platelet function, including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), aspirin, and other platelet inhibitors (e.g., clopidogrel), can potentiate the risk of bleeding.

Procedural and Timing Constraints

The risk of spinal or epidural hematomas is specifically increased when Lomoh is used in conjunction with neuraxial anesthesia or spinal puncture procedures. This risk is also higher with the concomitant use of any other drug affecting hemostasis. The official profile specifies requirements for concurrent use in certain settings, such as continuing Lomoh during the initiation of oral warfarin therapy until a therapeutic effect is achieved. Additionally, co-administration with oral aspirin therapy is specified for the management of certain acute coronary syndromes.

The substance functions through a highly specific biological mechanism to reduce enzymatic activity within the coagulation cascade. The primary mechanism involves it acting as a catalytic cofactor for the natural anticoagulant protein, Antithrombin III (AT-III). The molecule binds to AT-III, dramatically enhancing its ability to quickly and permanently neutralize Coagulation Factor Xa (FXa). This highly selective inhibition affects the cascade at an early enzymatic step. The molecular deactivation of Factor Xa leads to a profound reduction in the generation of Thrombin (Factor IIa), the enzyme responsible for converting soluble Fibrinogen into the insoluble Fibrin strands. This mechanism results in the physiological consequence of inhibited Fibrin formation, which reduces the structural foundation required for thrombus stabilization within the circulation. The molecule’s structure facilitates a strong preferential enzymatic affinity for Factor Xa over Thrombin (Factor IIa), and the mechanism demonstrates reduced activity against clotting factors that are already bound to a platelet surface or incorporated into a formed clot.

How to Use Lomoh: Administration Guidelines

This section outlines the instructions for administering Lomoh as specified in the approved use protocol.

Administration Scope

• Route of Administration: Lomoh is strictly for oral use.
• Preparation Requirements: The standard tablet formulation requires no prior preparation, such as dilution or reconstitution. The tablet must be swallowed whole with a glass of water.
• Timing and Frequency: The dose must be taken once daily, ideally at approximately the same time each day. It may be taken with or without food.

Dosing Rules by Age Group

• Note: Use in children under 2 years of age is not specified in the instructions.

Procedural Instructions

• Missed Dose: If a patient misses a dose, they must skip the missed dose entirely. The patient should not take a double dose to compensate. The regular dosing schedule must be resumed with the next scheduled dose at the usual time.
• Administration Steps:
  1. Determine the patient's age-appropriate dose (1.25 mg to 10 mg).
  2. Swallow the tablet whole, without crushing or chewing.
  3. Take with a glass of water.
  4. Repeat the process once daily at a consistent time.

Research evidence / Overview of studies

Research Focus and Activity

Studies have been conducted to evaluate the drug's activity. Research has evaluated the drug's activity in relation to specific physiological markers. In summary, research has focused on the drug as a subject of investigation for acute inflammatory conditions.

Some research has focused on the drug's characteristics.

Clinical Trials and Findings

Research has explored findings related to inflammation metrics. This involved evaluating patient reports and objective physiological measures across multiple international studies. Initial trials evaluated the drug’s effect, with some reporting positive findings, and research has assessed its profile in adults with acute conditions.

Safety and Event Profile

Safety studies have examined common side effects, with some reports detailing their severity and duration. Research assessed the rates of discontinuation or adverse events, with data focusing on gastric, hepatic, and cardiovascular events.

Drug Combination Studies

Research has compared this treatment approach to established methods. Studies evaluated the combination of the drug and physical therapy against established treatments, focusing on functional status over time. These evaluations specifically focused on whether the combination approach could influence movement and functional ability over a 12-month period.

Long-Term Follow-Up Data

Studies explored specific metrics related to condition status in patients with acute conditions, including follow-up on condition development. The follow-up periods for these studies ranged from six months to two years, focusing on disease recurrence and overall functional status.

Key Studies & References

1. Assessment of Safety and Tolerability Profile of Lomoh in Post-Marketing Surveillance: A Large Observational Study

Common questions about Lomoh (FAQ)

Q: How long until Lomoh starts to lower my blood pressure?

Lomoh typically starts to show an effect within the first week of starting treatment. The maximum blood pressure-lowering effect is typically observed within two to four weeks.

It is important to continue taking the medication daily as directed by a healthcare provider, and to follow up with them regularly to monitor your progress.

Q: Can I stop taking Lomoh once my blood pressure is normal?

Do not stop taking Lomoh without first consulting your healthcare provider, even if your blood pressure readings have returned to a normal range. High blood pressure is often a chronic condition requiring long-term treatment.

Stopping the medication suddenly may cause your blood pressure to rise (rebound hypertension), which could be a risk to your health. Consulting with your healthcare provider is necessary before making any changes to your dosage or stopping treatment.

How to Store and Dispose of Lomoh

Lomoh (Enoxaparin Sodium) must be stored at a Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). It is essential to not freeze this medication, and it must be protected from excessive heat and light.

To ensure product integrity, the pre-filled syringes must be kept in the original carton or packaging until the time of use. The medication is designated for single use only, and any unused portion must be immediately discarded.

For safety, Lomoh must be kept strictly out of the sight and reach of children.

Disposal requires adherence to specific protocols. All used syringes and needles must be placed immediately into a dedicated, puncture-resistant sharps disposal container. Patients must follow local requirements for the final disposal of full sharps containers, and the product must not be disposed of in household waste or waterways.